HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Ertapenem versus piperacillin/tazobactam for the treatment of complicated infections: a meta-analysis of randomized controlled trials.

AbstractBACKGROUND:
Ertapenem, a new carbapenem with a favorable pharmacokinetic profile, has been approved for the treatment of complicated intra-abdominal Infections (cIAIs), acute pelvic infections (APIs) and complicated skin and skin-structure infections (cSSSIs). The aim of this study is to compare the efficacy and safety of ertapenem with piperacillin/tazobactam, which has been reported to possess good efficacy for the treatment of these complicated infections.
METHODS:
We performed a meta-analysis of randomized controlled trials identified in PubMed, Cochrane library and Embase that compared the efficacy and safety of ertapenem with piperacillin/tazobactam for the treatment of complicated infections including cIAIs, APIs, cSSSIs. The primary efficacy outcome was clinical treatment success assessed at the test-of-cure visit. The primary safety outcome was drug related clinical and laboratory adverse events occurred during the treatment and the post-treatment period.
RESULT:
Six RCTs, involving 3161 patients, were included in our meta-analysis. Ertapenem was associated similar clinical treatment success with piperacillin/tazobactam for complicated infections treatment (clinically evaluable population, 1937 patients, odds ratios: 1.15, 95% confidence intervals: 0.89-1.49; modified intention to treat population, 2855 patients, odds ratios: 1.03, 95% confidence intervals: 0.87-1.22). All of secondary efficacy outcomes analysis obtained similar findings with clinical treatment success. No difference was found about the incidence of drug related adverse events between ertapenem and piperacillin/tazobactam groups.
CONCLUSION:
This meta-analysis provides evidence that ertapenem 1 g once a day can be used as effectively and safely as recommended dose of piperacillin/tazobactam, for the treatment of complicated infections, particularly of mild to moderate severity. It is an appealing option for the treatment of these complicated infections.
AuthorsMao Mao An, Zui Zou, Hui Shen, Jun Dong Zhang, Meng Li Chen, Ping Liu, Rui Wang, Yuan Ying Jiang
JournalBMC infectious diseases (BMC Infect Dis) Vol. 9 Pg. 193 (Dec 02 2009) ISSN: 1471-2334 [Electronic] England
PMID19951447 (Publication Type: Comparative Study, Journal Article, Meta-Analysis)
Chemical References
  • Anti-Bacterial Agents
  • beta-Lactams
  • Penicillanic Acid
  • Ertapenem
  • Tazobactam
  • Piperacillin
Topics
  • Anti-Bacterial Agents (therapeutic use)
  • Bacterial Infections (drug therapy)
  • Ertapenem
  • Humans
  • Penicillanic Acid (analogs & derivatives, therapeutic use)
  • Piperacillin (therapeutic use)
  • Randomized Controlled Trials as Topic
  • Tazobactam
  • Treatment Outcome
  • beta-Lactams (therapeutic use)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: